Published in Blood on March 12, 2010
Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels. FASEB J (2013) 2.16
In vivo roles of factor XII. Blood (2012) 1.37
Astrocyte elevated gene-1 promotes hepatocarcinogenesis: novel insights from a mouse model. Hepatology (2012) 1.32
The role of uPAR in epithelial-mesenchymal transition in small airway epithelium of patients with chronic obstructive pulmonary disease. Respir Res (2013) 1.15
VEGF-initiated angiogenesis and the uPA/uPAR system. Cell Adh Migr (2012) 0.94
Interaction of high-molecular-weight kininogen with endothelial cell binding proteins suPAR, gC1qR and cytokeratin 1 determined by surface plasmon resonance (BiaCore). Thromb Haemost (2011) 0.88
Pulmonary veins in the normal lung and pulmonary hypertension due to left heart disease. Am J Physiol Lung Cell Mol Physiol (2013) 0.84
Ferritin blocks inhibitory effects of two-chain high molecular weight kininogen (HKa) on adhesion and survival signaling in endothelial cells. PLoS One (2012) 0.84
Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells. Nat Commun (2016) 0.81
Physiologic activities of the contact activation system. Thromb Res (2014) 0.80
The role of AEG-1 in the development of liver cancer. Hepat Oncol (2016) 0.78
The structure of the FnI-EGF-like tandem domain of coagulation factor XII solved using SIRAS. Acta Crystallogr Sect F Struct Biol Cryst Commun (2013) 0.77
Factor XII gene mutation in the Hageman family. J Thromb Haemost (2011) 0.76
Domain 2 of uPAR regulates single-chain urokinase-mediated angiogenesis through β1-integrin and VEGFR2. Am J Physiol Heart Circ Physiol (2013) 0.76
Genotyping analysis for the 46 C/T polymorphism of coagulation factor XII and the involvement of factor XII activity in patients with recurrent pregnancy loss. PLoS One (2014) 0.76
Processing of Factor XII during Inflammatory Reactions. Front Med (Lausanne) (2016) 0.75
Antithrombotic potential of the contact activation pathway. Curr Opin Hematol (2016) 0.75
Factor XII bridges coagulation and fibrinolysis again. Blood (2010) 0.75
Heparan sulfate proteoglycans mediate factor XIIa binding to the cell surface. J Biol Chem (2015) 0.75
Serum stimulation of CCR7 chemotaxis due to coagulation factor XIIa-dependent production of high-molecular-weight kininogen domain 5. Proc Natl Acad Sci U S A (2016) 0.75
Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer. Oncotarget (2016) 0.75
SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell (2006) 10.50
Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem (1998) 8.30
Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med (2005) 3.59
WATERFALL SEQUENCE FOR INTRINSIC BLOOD CLOTTING. Science (1964) 3.44
Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A (2007) 3.36
EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell (2002) 3.21
Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci U S A (2006) 3.09
Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J (2007) 2.66
Dual role of collagen in factor XII-dependent thrombus formation. Blood (2009) 2.01
Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. Chem Biol (2005) 1.71
Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest (2008) 1.59
Epidermal growth factor receptor-dependent and -independent cell-signaling pathways originating from the urokinase receptor. J Biol Chem (2002) 1.50
The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J Biol Chem (1995) 1.45
Regulation of alpha5beta1 integrin conformation and function by urokinase receptor binding. J Cell Biol (2005) 1.44
A region in urokinase plasminogen receptor domain III controlling a functional association with alpha5beta1 integrin and tumor growth. J Biol Chem (2006) 1.38
Urokinase receptors are required for alpha 5 beta 1 integrin-mediated signaling in tumor cells. J Biol Chem (2006) 1.37
Domain 2 of the urokinase receptor contains an integrin-interacting epitope with intrinsic signaling activity: generation of a new integrin inhibitor. J Biol Chem (2005) 1.33
Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator. J Biol Chem (2005) 1.29
Improved quantification of angiogenesis in the rat aortic ring assay. Angiogenesis (2001) 1.29
Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. FASEB J (2000) 1.23
Plasma levels of bradykinin are suppressed in factor XII-deficient mice. Thromb Haemost (2006) 1.21
Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. Blood (2002) 1.19
The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J Biol Chem (1998) 1.17
Mapping the cell binding site on high molecular weight kininogen domain 5. J Biol Chem (1995) 1.13
Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling. J Biol Chem (2003) 1.12
Urokinase receptor primes cells to proliferate in response to epidermal growth factor. Oncogene (2006) 1.10
Assembly, activation, and signaling by kinin-forming proteins on human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol (2005) 1.06
The mitogen-activated protein kinase signaling pathways: role in megakaryocyte differentiation. J Thromb Haemost (2009) 1.04
Urokinase-type plasminogen activator receptor is involved in mediating the apoptotic effect of cleaved high molecular weight kininogen in human endothelial cells. Circ Res (2004) 1.01
beta1 integrin cytoplasmic domain residues selectively modulate fibronectin matrix assembly and cell spreading through talin and Akt-1. J Biol Chem (2009) 0.99
Human Hageman factor (factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells. J Biol Chem (1993) 0.98
Factor XII-induced mitogenesis is mediated via a distinct signal transduction pathway that activates a mitogen-activated protein kinase. Proc Natl Acad Sci U S A (1996) 0.92
Histidine-proline rich glycoprotein (HPRG) binds and transduces anti-angiogenic signals through cell surface tropomyosin on endothelial cells. Thromb Haemost (2004) 0.91
Mapping the interaction between high molecular mass kininogen and the urokinase plasminogen activator receptor. J Biol Chem (2004) 0.90
Sequences within domain II of the urokinase receptor critical for differential ligand recognition. J Biol Chem (2003) 0.90
Urokinase-type plasminogen activator receptor induces conformational changes in the integrin alphaMbeta2 headpiece and reorientation of its transmembrane domains. J Biol Chem (2008) 0.90
Oral thrombostatin FM19 inhibits prostate cancer. Thromb Haemost (2010) 0.82
Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med (2010) 5.23
Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem (2007) 2.10
A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res (2002) 2.05
Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. Blood (2004) 2.01
Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small (2009) 1.93
Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis. Blood (2011) 1.86
Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. J Clin Invest (2008) 1.77
Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem (2002) 1.67
Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain barrier damage, and inflammation. Blood (2012) 1.64
Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo. J Virol (2006) 1.63
Prolylcarboxypeptidase regulates food intake by inactivating alpha-MSH in rodents. J Clin Invest (2009) 1.63
Prolylcarboxypeptidase promotes angiogenesis and vascular repair. Blood (2013) 1.54
Expression and function of C5a receptor in mouse microvascular endothelial cells. J Immunol (2002) 1.53
Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood (2007) 1.48
Recombinant prolylcarboxypeptidase activates plasma prekallikrein. Blood (2004) 1.37
In vivo roles of factor XII. Blood (2012) 1.37
Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am J Pathol (2002) 1.33
Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin. Blood (2006) 1.24
Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. Blood (2002) 1.19
Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment. Drugs (2009) 1.18
The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1. J Pharmacol Exp Ther (2004) 1.17
D-dimer, P-selectin, and microparticles: novel markers to predict deep venous thrombosis. A pilot study. Thromb Haemost (2005) 1.17
Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol (2003) 1.16
Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field. Am J Clin Pathol (2005) 1.14
Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain. Cancer Res (2002) 1.14
Increased platelet and microparticle activation in HIV infection: upregulation of P-selectin and tissue factor expression. J Acquir Immune Defic Syndr (2012) 1.11
Identification of prolyl carboxypeptidase as an alternative enzyme for processing of renal angiotensin II using mass spectrometry. Am J Physiol Cell Physiol (2013) 1.10
Ordered adsorption of coagulation factor XII on negatively charged polymer surfaces probed by sum frequency generation vibrational spectroscopy. Anal Bioanal Chem (2007) 1.07
A novel pathway for human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies. Blood (2011) 1.07
Platelet-derived S100 family member myeloid-related protein-14 regulates thrombosis. J Clin Invest (2014) 1.06
The least of 3 evils: exposure to red blood cell transfusion, anemia, or both? J Thorac Cardiovasc Surg (2013) 1.06
Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes. Diabetes (2003) 1.06
Mitotic regulator SKAP forms a link between kinetochore core complex KMN and dynamic spindle microtubules. J Biol Chem (2012) 1.05
A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology (2002) 1.05
Detection of amide I signals of interfacial proteins in situ using SFG. J Am Chem Soc (2003) 1.05
The alternative medicine pawpaw and its acetogenin constituents suppress tumor angiogenesis via the HIF-1/VEGF pathway. J Nat Prod (2010) 1.03
Cutting edge: optical microspectrophotometry supports the existence of gel phase lipid rafts at the lamellipodium of neutrophils: apparent role in calcium signaling. J Immunol (2004) 1.02
Mammea E/BB, an isoprenylated dihydroxycoumarin protonophore that potently uncouples mitochondrial electron transport, disrupts hypoxic signaling in tumor cells. J Nat Prod (2010) 0.99
FcgammaRI ligation leads to a complex with BLT1 in lipid rafts that enhances rat lung macrophage antimicrobial functions. Blood (2009) 0.98
Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis. Thromb Res (2010) 0.98
Interaction of thrombin with PAR1 and PAR4 at the thrombin cleavage site. Biochemistry (2007) 0.97
AbetaPP/APLP2 family of Kunitz serine proteinase inhibitors regulate cerebral thrombosis. J Neurosci (2009) 0.97
Heparan sulfate modulates kinin release by Trypanosoma cruzi through the activity of cruzipain. J Biol Chem (2001) 0.96
Human tropomyosin isoforms in the regulation of cytoskeleton functions. Adv Exp Med Biol (2008) 0.95
Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis. Curr Opin Hematol (2007) 0.95
Immune thrombocytopenia in pregnancy. Hematol Oncol Clin North Am (2009) 0.94
Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2-/- mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation. Blood (2013) 0.94
Myeloperoxidase interacts with endothelial cell-surface cytokeratin 1 and modulates bradykinin production by the plasma Kallikrein-Kinin system. Am J Pathol (2007) 0.93
Approaches to synthetic platelet analogs. Biomaterials (2012) 0.93
Noonan syndrome/leukemia-associated gain-of-function mutations in SHP-2 phosphatase (PTPN11) enhance cell migration and angiogenesis. J Biol Chem (2008) 0.93
Identification of prolylcarboxypeptidase as the cell matrix-associated prekallikrein activator. FEBS Lett (2002) 0.92
Histidine-proline rich glycoprotein (HPRG) binds and transduces anti-angiogenic signals through cell surface tropomyosin on endothelial cells. Thromb Haemost (2004) 0.91
Effect of exercise training on aortic tone in chronic renal insufficiency. Am J Hypertens (2008) 0.91
Mechanisms of Arg-Pro-Pro-Gly-Phe inhibition of thrombin. Am J Physiol Heart Circ Physiol (2003) 0.90
Mapping the interaction between high molecular mass kininogen and the urokinase plasminogen activator receptor. J Biol Chem (2004) 0.90
The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin. Proc Natl Acad Sci U S A (2002) 0.90
Prolylcarboxypeptidase regulates proliferation, autophagy, and resistance to 4-hydroxytamoxifen-induced cytotoxicity in estrogen receptor-positive breast cancer cells. J Biol Chem (2010) 0.89
The relative priority of prekallikrein and factors XI/XIa assembly on cultured endothelial cells. J Biol Chem (2003) 0.88
Impaired fibrinolysis in the antiphospholipid syndrome. Curr Rheumatol Rep (2010) 0.87
A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP). Blood (2007) 0.87
Endothelial cell activation by antiphospholipid antibodies is modulated by Kruppel-like transcription factors. Blood (2011) 0.87
Immune thrombocytopenic purpura in pregnancy. Curr Opin Hematol (2007) 0.87
Upregulation of prolylcarboxypeptidase (PRCP) in lipopolysaccharide (LPS) treated endothelium promotes inflammation. J Inflamm (Lond) (2009) 0.87
Assembly and activation of the plasma kallikrein/kinin system: a new interpretation. Int Immunopharmacol (2002) 0.86
Mitochondrial respiration inhibitors suppress protein translation and hypoxic signaling via the hyperphosphorylation and inactivation of translation initiation factor eIF2α and elongation factor eEF2. J Nat Prod (2011) 0.86
Mapping the interaction of bradykinin 1-5 with the exodomain of human protease activated receptor 4. FEBS Lett (2005) 0.86
Anti-β2GPI antibodies stimulate endothelial cell microparticle release via a nonmuscle myosin II motor protein-dependent pathway. Blood (2013) 0.85
The plasma kallikrein/kinin and renin angiotensin systems in blood pressure regulation in sepsis. J Endotoxin Res (2004) 0.85
Natural and semisynthetic mammea-type isoprenylated dihydroxycoumarins uncouple cellular respiration. J Nat Prod (2011) 0.84
Synthesis of novel peptide inhibitors of thrombin-induced platelet activation. Chem Biol Drug Des (2006) 0.83
The marine sponge metabolite mycothiazole: a novel prototype mitochondrial complex I inhibitor. Bioorg Med Chem (2010) 0.83
Factor VLeiden inhibits fibrinolysis in vivo. Circulation (2004) 0.83
Comparing methods of measurement for detecting drug-induced changes in the QT interval: implications for thoroughly conducted ECG studies. Ann Noninvasive Electrocardiol (2004) 0.83
ACAP4 protein cooperates with Grb2 protein to orchestrate epidermal growth factor-stimulated integrin β1 recycling in cell migration. J Biol Chem (2011) 0.82
Oral thrombostatin FM19 inhibits prostate cancer. Thromb Haemost (2010) 0.82
Glycolysis inhibitor screening identifies the bis-geranylacylphloroglucinol protonophore moronone from Moronobea coccinea. J Nat Prod (2012) 0.82
Management and outcomes for patients with TTP: analysis of 100 cases at a single institution. Am J Hematol (2013) 0.81
Recent advances in the antiphospholipid antibody syndrome. Curr Opin Hematol (2014) 0.81
The Williams-Beuren Syndrome-a window into genetic variants leading to the development of cardiovascular disease. PLoS Genet (2012) 0.81